| Document Date: 2007-01-08 17:20:10
Open Document File Size: 32,22 KBShare Result on Facebook
City TOLEDO / CLEVELAND / FORT LAUDERDALE / / Company It Matters / AMD / Genentech / / Country United States / / Currency USD / / / IndustryTerm physician services / secondary insurance coverage / pharmaceutical costs / secondary insurance / pharmaceutical industries / imaging / Internet survey / / MedicalCondition cuts / exudative age-related macular degeneration / strokes / metastatic colon cancer / macular degeneration / exudative macular degeneration / Colon cancer / cut / heart attacks / angina / / MedicalTreatment chemotherapy / / Organization Congress / National Eye Institute / American Society of Retinal Specialists / FDA / Medicare / / Person STEPHEN R. KAUFMAN / JAMES G. RANDALL / J. GREGORY ROSENTHAL / LEON A. BYNOE / / Position Physician / / Product Visudyne / Macugen / Avastin / Lucentis / / ProvinceOrState Ohio / / RadioStation Am 2006 / / Technology chemotherapy / /
SocialTag |
A Avastin versus Lucentis: Why It Matters lthough Lucentis is a remarkably safe and effective treatment for exudative macular degeneration, it could cost our health care system over $9 billion, which